Celldex Therapeutics has presented mature overall survival data from a Phase II trial of rindopepimut (CDX-110) in patients with EGFRvIII-positive glioblastoma.
Rindopepimut is an immunotherapeutic vaccine that acts by targeting tumour-specific oncogene EGFRvIII.
Data from the multicentre, single-arm ACT III study demonstrated a median overall survival of 24.6 months from diagnosis, which is consistent with the finding of two earlier studies.
The study also revealed a two-year survival rate of 52%, again similar to the previous studies, which indicated a 50% survival rate at two years.
Rose Lai, lead investigator of the ACT III study, said that the data supported the validity of rindopepimut in EGFRvIII-positive glioblastoma patient population.
Celldex Therapeutics chief medical officer Thomas Davis said that the consistency of the data from the three trials clearly supports the company's plan to advance rindopepimut's clinical development with ACT IV, a pivotal, randomised, blinded and international Phase III study.